Home
About Us
Pipeline
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | R&D Programmes | Technologies & Capabilities | S*BIO’s Functional Capabilities | Publications |
| Investors | Partnerships |
| News & Press Releases | Participation in Events |
| Join Our Team | Job Openings | How to Apply |
 |
 |
|
A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it. Max Planck |
|
|
|
Publications Biological and Pharmaceutical Bulletin 2007; 30(5): 1021—1024 In vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species P. Venkatesh, Evelyn Goh, Peizi Zeng, Lee Sun New, Liu Xin, Mohammed Khalid Pasha, Kanda Sangthongpitag, Pauline Yeo, and Ethirajulu Kantharaj Biomedical Chromatography. 2007; 21(2): 184-189 Development and validation of high performance liquid chromatography tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies Pauline Yeo, Liu Xin, Evelyn Goh, Lee Sun New, Peizi Zeng, Xiaofeng Wu, P. Venkatesh and Ethirajulu Kantharaj
|
